

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

Claim 1 (currently amended): A site-specific drug delivery medical device having a coating consisting essentially of rosiglitazone and at least one biocompatible polymer wherein said site-specific drug delivery device is a stent.

Claim 2-5 (cancelled):

Claim 5 (cancelled):

Claim 6 (currently amended): The site-specific drug delivery medical device according to claim [[5]] 1 wherein said stent is a vascular stent or biliary stent.

Claim 7 (previously presented): The site-specific drug delivery medical device according to claim 6 wherein said vascular stent is provided with a coating consisting essentially of rosiglitazone and at least one biocompatible polymer.

Claim 8 (cancelled)

Claim 9 (previously presented): The site-specific drug delivery medical device according to claim 1 wherein said biocompatible polymer is selected from the group consisting of polyvinyl pyrrolidone, polytetrafluoroethylene, poly-L-lactic acid, polycaprolactone, polyethylene glycol, polystyrene, acrylates, polyesters and mixtures thereof.

Claim 10 (cancelled)

Claim 11 (previously presented): A vascular stent consisting essentially of rosiglitazone; and

a polymer selected from the group consisting of polyvinyl pyrrolidone, polytetrafluoroethylene, poly-L-lactic acid, polycaprolactone, polyethylene glycol, polystyrene, acrylates, polyesters and mixtures thereof.

Claims 12-26 (cancelled)

Claim 27 (previously presented): The site-specific drug delivery medical device according to claim 7 wherein said biocompatible polymer is selected from the group consisting of polyvinyl pyrrolidone, polytetrafluoroethylene, poly-L-lactic acid, polycaprolactone, polyethylene glycol, polystyrene, acrylates, polyesters and mixtures thereof.